[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [TECHNOLOGY]

2 clusters · 5 sources · 9 days · First seen · Last updated

AI and automation in antibody discovery

Overview

The biotechnology sector is increasingly integrating artificial intelligence and automation to enhance antibody discovery and development.

In late September 2026, Ginkgo Datapoints and Apheris launched the Antibody Developability Consortium. This industry collaboration, involving members such as AbbVie, argenx, Lundbeck, and Takeda, aims to create a standardized dataset of approximately 10,000 antibodies. By utilizing privacy-preserving federated data networks, the consortium seeks to build more robust AI models to better predict manufacturability and developability risks in antibody candidates.

Following this, Danaher Corporation announced plans to launch an AI-powered autonomous laboratory by early 2027. Operating through its subsidiary Abcam, the facility will employ a ‘design-make-test-learn’ loop that combines AI-driven design with robotic execution. This automated workflow is intended to significantly accelerate affinity reagent discovery and increase annual output.

Entities

University of Oxford · AbbVie · DaltonTx · Apheris · Danaher Corporation

Timeline

  1. [TECHNOLOGY] 2 sources
    Danaher to launch AI-powered autonomous antibody lab in 2027

    Danaher Corporation plans to open an AI-driven autonomous laboratory by 2027 to accelerate antibody discovery through a continuous robotic ‘design-make-test-learn’ cycle.

  2. [TECHNOLOGY] 3 sources
    Antibody Developability Consortium launched to advance AI-powered drug discovery

    Ginkgo Datapoints and Apheris have launched the Antibody Developability Consortium to build a massive AI-ready dataset for predicting antibody manufacturability.

Sources

cryptopolitan.com · drug-dev.com · genengnews.com · tech.eu · xconomy.com